| Schedule of segment revenue, segment loss, and significant segment expenses |
| | | | | | | | | | | | | | | Three Months Ended June 30, | | Six Months Ended June 30, | | | 2026 | | 2025 | | 2026 | | 2025 | Revenues: | | | | | | | | | | | | | Product sales, net | | $ | 170,382 | | $ | 6,517 | | $ | 300,263 | | $ | 6,517 | Service revenue, net | | | 1,297 | | | 2,320 | | | 4,281 | | | 5,440 | Total revenue | | | 171,679 | | | 8,837 | | | 304,544 | | | 11,957 | Cost of product sales | | | 10,759 | | | 205 | | | 21,838 | | | 205 | Cost of service revenue | | | 791 | | | 1,292 | | | 1,564 | | | 2,809 | Program expenses (1) | | | | | | | | | | | | | YUTREPIA | | | 19,327 | | | 14,661 | | | 35,215 | | | 24,419 | L606 | | | 10,777 | | | 2,793 | | | 16,599 | | | 6,061 | Generic Treprostinil | | | 9 | | | 125 | | | (40) | | | 276 | Total program expenses | | | 30,113 | | | 17,579 | | | 51,774 | | | 30,756 | Non-program expenses (2) | | | 8,801 | | | 5,835 | | | 14,998 | | | 9,605 | Personnel, including stock-based compensation | | | 35,698 | | | 21,431 | | | 67,349 | | | 41,512 | Income (loss) from operations | | | 85,517 | | | (37,505) | | | 147,021 | | | (72,930) | Other income (expense), net | | | (3,820) | | | (4,074) | | | (8,542) | | | (7,016) | Income (loss) before income taxes | | $ | 81,697 | | $ | (41,579) | | $ | 138,479 | | $ | (79,946) | Income tax expense | | | 6,975 | | | — | | | 10,895 | | | — | Net income (loss) | | $ | 74,722 | | $ | (41,579) | | $ | 127,584 | | $ | (79,946) |
| (1) | Includes external research and development and selling, general and administrative expenses |
| (2) | Includes professional service fees, facilities & infrastructure expenses, insurance, depreciation & amortization, and other corporate expenses |
|